05:02 , Jan 19, 2018 |  BC Week In Review  |  Company News

Context acquires onapristone from Arno

Cancer company Context Therapeutics (Philadelphia, Pa.) acquired worldwide rights to Apristor onapristone XR from Arno Therapeutics Inc. (Flemington, N.J.) for an undisclosed one-time payment. In December, Arno announced that it would dissolve and turn over...
00:45 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Onapristone: Ph II halted

Arno said it halted enrollment in the Phase II portion of an open-label, U.K. Phase I/II trial evaluating twice-daily onapristone plus Zytiga abiraterone acetate after the company determined further enrollment was not justified based on...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Arno completes private placement of units

Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J.   Business: Cancer, Infectious   Date completed: 2016-08-16   Type: Private placement of units   Raised: $2.8 million   Units: 7.9 million   Price: $0.35 (unit)   Shares after...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Onapristone: Phase I/II discontinued

Arno discontinued an open-label, French Phase I/II trial of onapristone in patients with endometrial cancer to focus on clinical development of onapristone to treat metastatic castration-resistant prostate cancer (CRPC) that has become resistant to Zytiga...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Arno completes private placement

Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J.   Business: Cancer   Date completed: 2016-01-13   Type: Private placement   Raised: $5.3 million   Shares: 15.1 million   Price: $0.35   Shares after offering: 41.6 million  ...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Arno preclinical data

In human CF macrophages, Arno said AR-13 in combination with broad-spectrum antibiotics synergistically reduced antibiotic-resistant Burkholderia cenocepacia burden. In CF neutrophils, AR-13 alone significantly reduced Pseudomonas aeruginosa burden by 70%. Data were presented at the...
00:55 , Sep 18, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Marathon Pharmaceuticals LLC (Northbrook, Ill.) named Jordon Dubow CMO and VP of clinical and medical affairs. Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Onapristone ER: Phase I/II amended

Arno amended and began the dose-expansion stage of an open-label, dose-escalation, U.K. Phase I/II trial evaluating 10, 20, 30, 40 and 50 mg oral onapristone ER twice daily with and without Zytiga abiraterone in about...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Onapristone: Additional Phase I data

Additional data from 52 evaluable postmenopausal women with progesterone receptor-positive tumors in the Phase I portion of an open-label, dose-escalation, French Phase I/II trial showed that oral onapristone led to a median PFS of 57.5...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Onapristone ER: Phase I data

Data from 21 patients who had failed Zytiga abiraterone or Xtandi enzalutamide treatment in the dose-escalation Phase I portion of an open-label, U.K. Phase I/II trial showed that 10, 20, 30, 40 and 50 mg...